Early Signals
Explore the emerging innovations, behaviours, and market shifts shaping the future of health, wellness, and fitness, turning fragmented early signals into structured foresight before they become obvious to the wider market.
To receive early signals weekly in your inbox, sign up to our newsletter, The Pulse.
Sector
Sector
Sub Sector
Trends
Macro Trends
Micro Trends
Signal
Signal Type
Signal Region
Membership
Membership Level
Date
Date Range
Vicore and Alex reported positive pilot results for a CBT-based digital therapeutic designed to support anxiety in idiopathic pulmonary fibrosis patients. The signal points toward digital therapeutics moving beyond broad wellness use cases into disease-linked mental health support, where clinical need, pathway clarity and measurable outcomes are easier to define.
Lilly has reported Phase 3 data for Foundayo, its oral GLP-1 candidate orforglipron, ahead of the ADA Scientific Sessions, positioning it as an oral incretin therapy without food or water restrictions. The signal points toward a more scalable, choice-led phase of obesity and diabetes treatment, where delivery format becomes a major adoption driver.
Lucis has raised $20m to scale its AI-powered preventive health platform across Europe, combining 110-plus blood biomarkers with personalised guidance, while Cardio Diagnostics is positioning precision cardiovascular testing in the employer benefits market. Together, the signal suggests blood biomarkers are being repackaged from clinical diagnostics into AI-led prevention, consumer engagement and population-risk management.
PolyBio has launched the VIPER programme to validate biomarkers for Long COVID, aiming to establish objective biological measures for diagnosis and research. The initiative signals growing efforts to move Long COVID from a symptom-defined condition toward a biomarker-supported clinical category.
SPRIND has opened applications for a Continuous Hormone Monitoring challenge, funding teams to develop sensors that can measure at least four hormones continuously over seven days. The signal points toward hormone monitoring moving beyond static lab tests and fertility tracking into a more ambitious infrastructure layer for women’s health, endocrine care and personalised prevention.
Nike and Hyperice have launched the Hyperboot, a wearable recovery boot combining active heat and compression in footwear form. The signal points toward recovery moving from static at-home devices into wearable performance products designed for warm-up, readiness and everyday athlete routines.